A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

NCT00630825 on ClinicalTrials.gov · last registry update 2014-12-10

An unusually large phase 2: 262 participants, more than double the 110 typical for the stage. The sponsor logged completion for January 2009. Primary outcome, as filed: Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 262
Started: 2008-04
Primary completion: 2009-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Conditions studied

Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.